BRIEF-Antares Pharma ‍says received FDA letter regarding deficiencies of its drug Xyosted

From Reuters - October 12, 2017

Oct 12 (Reuters) - Antares Pharma Inc

* Antares Pharma provides Xyosted regulatory update

* Antares Pharma Inc - anticipate receiving further clarification from FDA on or before prescription drug user fee act (PDUFA) date of October 20, 2017

* Antares Pharma Inc - intends to work with FDA to understand nature of deficiencies once identified


Continue reading at Reuters »